Spondyloarthritis & psoriatic arthritis
Construct validity and responsiveness of feasible composite disease activity measures for use in daily clinical practice in patients with psoriatic arthritis
Authors' conclusion
Both measures have promising performance characteristics, showing strong correlations and good discrimination with existing composite measures.
Study context
- Population
- Patients with newly diagnosed PsA receiving usual care
- Participants
- 629 patients
- Comparison
- 3VAS and 4VAS vs other composite disease activity measures
- Outcome
- Construct validity and responsiveness of the 3VAS and 4VAS
- Follow-up
- 3-month interval
Methodological detailsconstruct validity and responsiveness (3-month interval), Spearman correlation coefficients, standardised response means with effect sizes
- Construct validity and responsiveness (3-month interval)
- Spearman correlation coefficients
- Standardised response means with effect sizes
Performance
As reported in the abstract
Responsiveness
| Test or model | Effect sizes (ES) | Standardised response means (SRM) |
|---|---|---|
| 3VAS | 0.48 | 0.52 |
| 4VAS | 0.48 | 0.50 |
Effect sizes (ES)
3VAS0.48
4VAS0.48
Standardised response means (SRM)
3VAS0.52
4VAS0.50
Further findings
Construct validity: correlation with other composite measures (both 3VAS and 4VAS)
- Spearman r with Disease Activity in PSoriatic Arthritis (DAPSA)
- r=0.80-0.87
- Spearman r with Psoriatic Arthritis Disease Activity Score (PASDAS)
- r=0.89
- Spearman r with RAPID3
- r=0.84-0.92
Agreement in categorising low disease activity (LDA) · 12 months
- 3VAS and 4VAS had the highest agreement with PASDAS
Original publication
Construct validity and responsiveness of feasible composite disease activity measures for use in daily clinical practice in patients with psoriatic arthritis. RMD Open. Published 25 October 2023. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →